152 related articles for article (PubMed ID: 11251017)
1. Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
Simon RM; Steinberg SM; Hamilton M; Hildesheim A; Khleif S; Kwak LW; Mackall CL; Schlom J; Topalian SL; Berzofsky JA
J Clin Oncol; 2001 Mar; 19(6):1848-54. PubMed ID: 11251017
[TBL] [Abstract][Full Text] [Related]
2. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial designs for therapeutic cancer vaccines.
Simon R
Cancer Treat Res; 2005; 123():339-50. PubMed ID: 16211877
[TBL] [Abstract][Full Text] [Related]
4. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
5. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
[No Abstract] [Full Text] [Related]
6. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
Moschella F; Proietti E; Capone I; Belardelli F
Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
[TBL] [Abstract][Full Text] [Related]
7. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
8. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
9. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in therapeutic cancer vaccines.
Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
[TBL] [Abstract][Full Text] [Related]
11. Whole-cell vaccines: A failure or a success waiting to happen?
Copier J; Dalgleish A
Curr Opin Mol Ther; 2010 Feb; 12(1):14-20. PubMed ID: 20140812
[TBL] [Abstract][Full Text] [Related]
12. Cancer vaccines: a new frontier in prevention and treatment.
Giarelli E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):11-7; discussion 18. PubMed ID: 18154203
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
14. Newer phase II trial designs gaining ground.
Benowitz S
J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
[No Abstract] [Full Text] [Related]
15. Evaluation of randomized discontinuation design.
Freidlin B; Simon R
J Clin Oncol; 2005 Aug; 23(22):5094-8. PubMed ID: 15983399
[TBL] [Abstract][Full Text] [Related]
16. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.
Bilusic M; Gulley JL
Cancer Immunol Immunother; 2012 Jan; 61(1):109-17. PubMed ID: 22120693
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial designs for multiple myeloma.
Hoering A; Crowley J
Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
[TBL] [Abstract][Full Text] [Related]
18. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Strategy Group Workshop--'Clinical endpoints in trials of biological agents'.
Br J Cancer; 2000 Aug; 83(3):294-7. PubMed ID: 10917541
[No Abstract] [Full Text] [Related]
19. Vaccines: an innovative approach to treating cancer.
Pazdur MP; Jones JL
J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
[TBL] [Abstract][Full Text] [Related]
20. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
